SSB
VERV

Sandy Spring Bank’s Verve Therapeutics VERV Stock Holding History

Sandy Spring Bank’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$11.9K Hold
2,600
– – ﹤0.01% 816
2024
Q4 		$14.7K Sell
2,600
-800
-24% -$4.51K ﹤0.01% 804
2024
Q3 		$16.5K Buy
3,400
+800
+31% +$4.65K ﹤0.01% 776
2024
Q2 		$12.7K Hold
2,600
– – ﹤0.01% 842
2024
Q1 		$34.5K Buy
2,600
+400
+18% +$5.3K ﹤0.01% 655
2023
Q4 		$30.7K Hold
2,200
– – ﹤0.01% 644
2023
Q3 		$29.2K Hold
2,200
– – ﹤0.01% 646
2023
Q2 		$41.3K Hold
2,200
– – ﹤0.01% 581
2023
Q1 		$31.7K Hold
2,200
– – ﹤0.01% 615
2022
Q4 		$42.6K Hold
2,200
– – ﹤0.01% 560
2022
Q3 		$76K Hold
2,200
– – ﹤0.01% 446
2022
Q2 		$34K Hold
2,200
– – ﹤0.01% 590
2022
Q1 		$50K Hold
2,200
– – ﹤0.01% 543
2021
Q4 		$81K Buy
2,200
+600
+38% +$25.2K ﹤0.01% 483
2021
Q3 		$75K Hold
1,600
– – ﹤0.01% 476
2021
Q2 		$96K Buy
+1,600
New +$66.4K 0.01% 439

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sandy Spring Bank's VERV Position: Q1 2025 in Review

Sandy Spring Bank held its Verve Therapeutics (VERV) position steady in Q1 2025 at 2,600 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #816.

Sandy Spring Bank first reported a position in VERV in Q2 2021 and has held it in 16 quarters since. The position peaked at $96K in Q2 2021. 191 funds tracked by Wall St. Rank hold VERV as of Q1 2025.

  • Sandy Spring Bank held 2,600 shares of Verve Therapeutics worth $11.9K as of Q1 2025.
  • Sandy Spring Bank left its Verve Therapeutics share count unchanged in Q1 2025.
  • Verve Therapeutics made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #816 holding.
  • Sandy Spring Bank first reported a position in Verve Therapeutics in Q2 2021 and has held it in 16 quarters since.
  • Sandy Spring Bank's Verve Therapeutics position peaked at $96K in Q2 2021.
  • 191 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.